Breaking the GLP-1 Cost Cycle

  • White Paper
  • GLP-1s

Summary

Noom’s Breaking the GLP-1 Cost Cycle white paper dives into the scale of the obesity crisis and how Noom’s two tailored solutions can enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications.

Breaking the GLP-1 cost cycle graphic

Obesity is a complex, multifactorial disease that requires comprehensive medical attention and innovative treatment strategies. Within the next five years, we anticipate a seismic shift in healthcare: most organizations will extend coverage for GLP-1 medications to treat obesity. This change is inevitable as non-branded alternatives emerge and costs decrease. 

To meet diverse employer needs, Noom is unveiling two tailored solutions, which can be supported either through an organization’s current pharmacy benefit manager (PBM) or through a full carve-out for GLP-1 weight loss medications. Both enable affordable access to GLP-1 medications. 

  • Solution 1, Noom Med with an optional SmartRx plan, is designed to drive ROI for employers who cover GLP-1s. 
  • Solution 2, Noom Weight with discounted access to employee-pay meds, is designed as a workforce-friendly, budget-conscious solution for employers who do not cover GLP-1s. 

In our latest white paper, you’ll learn more about Noom’s solutions, and how to significantly boost your ROI and broaden access to GLP-1s now, regardless of your organization’s current coverage policies for obesity medications.

At Noom, we do not wait for tomorrow—we act today. Download now and find out how Noom helps address diverse employer needs while positioning you ahead of the curve as treatment options evolve.

Download the White Paper

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

Related Content

  • Blog
  • Noom Weight
  • October 1
  • 1 min read

Noom Weight Loss Study: Promising Results Among Breast Cancer Survivors

Post-diagnosis weight gain is common in early-stage breast cancer and is associated with increased risk of recurrence and mortality. Intentional weight loss is difficult to maintain, and digital lifestyle interventions may provide a scalable approach to address this challenge. Navigating the path to better health can be challenging, but with the right tools and support, […]

By Noom Team
  • Blog
  • October 1
  • 1 min read

From Weight Loss to Risk: Understanding GLP-1’s Impact on Eating Disorders

Weight loss medication abuse is not new. Diet pills, caffeine, laxatives, and others have been around for a long time, but with the emergence of GLP-1s, more reports of disordered eating have surfaced. While these drugs have helped millions of individuals reach their weight loss goals, many suffer side effects that ultimately lead them to discontinue use, resulting not only in money lost, but weight regain. In this post, we'll deep dive into the discussion around GLP-1s and eating disorders, to ensure that employers, providers and health plans have access to the right support for members on GLP-1s.

By Noom Team
  • Webinar
  • Mental Health
  • October 1
  • 1 min read

Building a More Resilient Workforce – How do you do it?

Workplace stress is estimated to cost the US $190 billion and leads to more than 120,000 deaths annually. In a post-COVID-19 world, our well-being is under attack due to many factors, and the stress it creates is wearing down on employee health and productivity. Organizations need proven interventions to reduce workplace stress and build employees’ […]

By Noom Team

Bring Noom to
your organization

Give your workforce a preview of what’s possible
for their physical and mental health.

REQUEST DEMO